Skip to Content
Find More Like This
Return to Search

Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles

United States Patent

9,549,976
January 24, 2017
View the Complete Patent at the US Patent & Trademark Office
Sandia National Laboratories - Visit the Intellectual Property Management and Licensing Website
The invention relates to virus-like particles of bacteriophage MS2 (MS2 VLPs) displaying peptide epitopes or peptide mimics of epitopes of Nipah Virus envelope glycoprotein that elicit an immune response against Nipah Virus upon vaccination of humans or animals. Affinity selection on Nipah Virus-neutralizing monoclonal antibodies using random sequence peptide libraries on MS2 VLPs selected peptides with sequence similarity to peptide sequences found within the envelope glycoprotein of Nipah itself, thus identifying the epitopes the antibodies recognize. The selected peptide sequences themselves are not necessarily identical in all respects to a sequence within Nipah Virus glycoprotein, and therefore may be referred to as epitope mimics VLPs displaying these epitope mimics can serve as vaccine. On the other hand, display of the corresponding wild-type sequence derived from Nipah Virus and corresponding to the epitope mapped by affinity selection, may also be used as a vaccine.
Peabody; David S. (Albuquerque, NM), Chackerian; Bryce (Albuquerque, NM), Ashley; Carlee (Albuquerque, NM), Carnes; Eric (Albuquerque, NM), Negrete; Oscar (Livermore, CA)
STC.UNM (Albuquerque, NM), SANDIA CORPORATION (Albuquerque, NM)
14/ 081,629
November 15, 2013
PRIORITY CLAIM AND GOVERNMENT INTEREST This invention was made with government support under Grant Nos. R01 GM042901 and R01 AI08335 awarded by the National Institute of Health and Grant No. DE-AC04-94AL85000 awarded by the Department of Energy to Sandia Corporation. The government has certain rights in the invention.